200 related articles for article (PubMed ID: 32339645)
1. Toll-Like Receptor Agonists and Radiation Therapy Combinations: An Untapped Opportunity to Induce Anticancer Immunity and Improve Tumor control.
Walshaw RC; Honeychurch J; Choudhury A; Illidge TM
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):27-37. PubMed ID: 32339645
[TBL] [Abstract][Full Text] [Related]
2. Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy.
Jeon D; Hill E; Moseman JE; McNeel DG
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38702146
[TBL] [Abstract][Full Text] [Related]
3. The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies.
Martinsen JT; Gunst JD; Højen JF; Tolstrup M; Søgaard OS
Front Immunol; 2020; 11():1112. PubMed ID: 32595636
[TBL] [Abstract][Full Text] [Related]
4. Recent Findings on the Application of Toll-like Receptors Agonists in Cancer Therapy.
Mikulandra M; Pavelic J; Glavan TM
Curr Med Chem; 2017; 24(19):2011-2032. PubMed ID: 28322156
[TBL] [Abstract][Full Text] [Related]
5. Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy.
Kirtland ME; Tsitoura DC; Durham SR; Shamji MH
Front Immunol; 2020; 11():599083. PubMed ID: 33281825
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapy.
Tran TH; Tran TTP; Truong DH; Nguyen HT; Pham TT; Yong CS; Kim JO
Acta Biomater; 2019 Aug; 94():82-96. PubMed ID: 31129358
[TBL] [Abstract][Full Text] [Related]
7. Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer.
Roses RE; Xu M; Koski GK; Czerniecki BJ
Oncogene; 2008 Jan; 27(2):200-7. PubMed ID: 18176601
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy and toll-like receptor agonists.
Marabelle A; Filatenkov A; Sagiv-Barfi I; Kohrt H
Semin Radiat Oncol; 2015 Jan; 25(1):34-9. PubMed ID: 25481264
[TBL] [Abstract][Full Text] [Related]
9. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
[TBL] [Abstract][Full Text] [Related]
10. The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus.
Domingues R; de Carvalho GC; da Silva Oliveira LM; Futata Taniguchi E; Zimbres JM; Aoki V; da Silva Duarte AJ; Sato MN
Br J Dermatol; 2015 Jan; 172(1):48-55. PubMed ID: 24976336
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expression.
Jeon D; McNeel DG
Oncoimmunology; 2022; 11(1):2054758. PubMed ID: 35340661
[TBL] [Abstract][Full Text] [Related]
12. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptor agonists synergize with CD40L to induce either proliferation or plasma cell differentiation of mouse B cells.
Boeglin E; Smulski CR; Brun S; Milosevic S; Schneider P; Fournel S
PLoS One; 2011; 6(10):e25542. PubMed ID: 21991317
[TBL] [Abstract][Full Text] [Related]
14. In vivo cancer vaccination: Which dendritic cells to target and how?
Chiang CL; Kandalaft LE
Cancer Treat Rev; 2018 Dec; 71():88-101. PubMed ID: 30390423
[TBL] [Abstract][Full Text] [Related]
15. Differential Effects of Toll-Like Receptor Signaling on the Activation of Immune Responses in the Upper Respiratory Tract.
Xu M; Li N; Fan X; Zhou Y; Bi S; Shen A; Wang B
Microbiol Spectr; 2022 Feb; 10(1):e0114421. PubMed ID: 35196817
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptors (TLRs) in cancer; with an extensive focus on TLR agonists and antagonists.
Keshavarz A; Pourbagheri-Sigaroodi A; Zafari P; Bagheri N; Ghaffari SH; Bashash D
IUBMB Life; 2021 Jan; 73(1):10-25. PubMed ID: 33217774
[TBL] [Abstract][Full Text] [Related]
17. Toll-like receptor agonists: a patent review (2011 - 2013).
Hussein WM; Liu TY; Skwarczynski M; Toth I
Expert Opin Ther Pat; 2014 Apr; 24(4):453-70. PubMed ID: 24456079
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma.
Deng S; Zhu S; Qiao Y; Liu YJ; Chen W; Zhao G; Chen J
Protein Cell; 2014 Dec; 5(12):899-911. PubMed ID: 25411122
[TBL] [Abstract][Full Text] [Related]
19. Chemical Strategies to Enhance the Therapeutic Efficacy of Toll-like Receptor Agonist Based Cancer Immunotherapy.
Lee SN; Jin SM; Shin HS; Lim YT
Acc Chem Res; 2020 Oct; 53(10):2081-2093. PubMed ID: 32966047
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptor agonists in cancer therapy.
Adams S
Immunotherapy; 2009 Nov; 1(6):949-64. PubMed ID: 20563267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
